Medindia

X

SGX Pharmaceuticals to Present at Two Upcoming Investor Conferences

Wednesday, November 21, 2007 General News J E 4
Advertisement
SAN DIEGO, Nov. 21 SGX Pharmaceuticals, Inc.(Nasdaq: SGXP) announced today that the company will be presenting at twoupcoming investor conferences during which Mike Grey, president & chiefexecutive officer of SGX Pharmaceuticals, will provide an overview of theCompany's oncology pipeline. The conference information is as follows:

A live webcast of the Lazard presentation will be available under theinvestor relations section of the Company's website athttp://www.sgxpharma.com. Replays of the presentation will be available for 90days following the event. Please connect to the Company's website severalminutes prior to the start of the broadcast to ensure adequate time for anysoftware download that may be necessary.

About SGX Pharmaceuticals

SGX Pharmaceuticals is a biotechnology company focused on the discovery,development and commercialization of innovative cancer therapeutics. The SGXoncology pipeline includes drug candidates from its FAST(TM) drug discoveryplatform, such as next generation BCR-ABL inhibitors being developed by SGXand in partnership with Novartis and MET tyrosine kinase inhibitors, includingSGX523, and JAK2 inhibitors. More information on the pipeline and drugdiscovery platform can be found at http://www.sgxpharma.com and in theCompany's various filings with the Securities and Exchange Commission.-- 19th Annual Piper Jaffray Health Care Conference Presentation: Tuesday, November 27, 2007 at 11:30 AM Eastern Standard Time at The Pierre New York, New York City. -- Lazard Capital Markets Fourth Annual Healthcare Conference Presentation: Wednesday, November 28, 2007 at 1:30 PM Eastern Standard Time at the New York Palace Hotel in New York City.

SOURCE SGX Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Par Pharmaceutical Files Form 10-Qs for First and ...
S
PR Newswire Broadcast Minute and Podcast for Wedne...